ZyVersa Therapeutics, Inc. (ZVSA)
NASDAQ: ZVSA · Real-Time Price · USD
1.140
-0.100 (-8.06%)
At close: Dec 20, 2024, 4:00 PM
1.062
-0.078 (-6.86%)
After-hours: Dec 20, 2024, 7:59 PM EST
ZyVersa Therapeutics Employees
ZyVersa Therapeutics had 7 employees as of December 31, 2023. The number of employees did not change compared to the previous year.
Employees
7
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$3,047,177
Market Cap
2.67M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 7 | 0 | - |
| Dec 31, 2022 | 7 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| iSpecimen | 53 |
| Matinas BioPharma Holdings | 32 |
| Scinai Immunotherapeutics | 31 |
| LogicMark | 27 |
| ENDRA Life Sciences | 21 |
| Windtree Therapeutics | 20 |
| InMed Pharmaceuticals | 13 |
| Entero Therapeutics | 9 |
ZVSA News
- 3 days ago - ZyVersa Therapeutics' CEO, Stephen C. Glover, to Attend JPM's Healthcare Conference 2025 in San Francisco - GlobeNewsWire
- 4 weeks ago - ZyVersa Therapeutics Announces Peer-Reviewed Publication Demonstrating That Inflammasome ASC Inhibitor IC 100 Protects Against Stroke-Related Cardiovascular Injury and Dysfunction in Preclinical Trial - GlobeNewsWire
- 5 weeks ago - ZyVersa Therapeutics Reports Third Quarter, 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 6 weeks ago - ZyVersa Therapeutics Highlights Published Data Demonstrating the Potential of Inflammasome Inhibition to Protect Pancreatic Islet Beta Cells and Attenuate Progression from Obesity to Insulin Resistance and Type 2 Diabetes - GlobeNewsWire
- 7 weeks ago - ZyVersa Therapeutics Highlights Review Article Supporting the Need for Drug Therapies to Treat the Inflammation of Obesity in Addition to Weight Loss Drugs - GlobeNewsWire
- 2 months ago - ZyVersa Therapeutics Highlights Published Data Demonstrating That Obesity Results in Neuroinflammation Implicated in Development of Neurodegenerative Diseases - GlobeNewsWire
- 2 months ago - ZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter to Shareholders Highlighting Obesity Development Plans for Inflammasome ASC Inhibitor IC 100 Over the Next Nine Months - GlobeNewsWire
- 2 months ago - ZyVersa Therapeutics CEO, Stephen C. Glover, Was a Featured Guest on The Big Biz Show to Discuss Current Trends in the Obesity Drug Market and the Potential Role of Inflammasome Inhibitors - GlobeNewsWire